Ashwani Verma

Asthika Goonewardene

Michael Schmidt

Peter Lawson

Sudan Loganathan

Yaron Werber

Akash Tewari

David Lebowitz

Gregory Renza

Sean Laaman

Stephen Willey

Andrew Berens

Chi Meng Fong

Derek Archila

Jason Gerberry

Silvan Tuerkcan

Tsan-Yu Hsieh

Anastasia Parafestas

Andy Hsieh

Andy Shay

Anish Nikhanj

Cheng Li

Chris Shibutani

Etzer Darout

Eva Fortea-Verdejo

Jay Olson

Joseph Catanzaro

Silvan Türkcan

- Exelixis is a commercial-stage oncology biotech with its flagship molecule, **cabozantinib (Cabo)**, holding **seven indications** and leading the kidney cancer market.  **[939767_2155796_1]** 
- Cabo recently launched a new indication in **neuroendocrine tumors (NETs)** at the end of Q1, with the launch progressing well despite initial sell-side confusion on expectations.  **[939767_2155796_4]** 
- The company is developing **zanzalintinib (Zanza)**, a next-generation molecule, to manage the **2031 patent expiry of Cabo**.  **[939767_2155796_1]** **[939767_2155796_2]** 
- Zanza's STELLAR-303 trial for **colorectal cancer (CRC)** achieved a "big win" in the ITT population, with results to be presented at ESMO next month.  **[939767_2155796_5]** **[939767_2155796_6]** 
- Exelixis has been **profitable for the past seven to eight years** and commits approximately **$1 billion annually to R&D**, focusing on disciplined capital allocation and strategic clinical collaborations to expand its pipeline.  **[939767_2155796_1]** **[939767_2155796_2]** **[939767_2155796_3]** **[939767_2155796_7]**

Exelixis Discusses Flagship Product Cabozantinib, Next-Generation Zanzalintinib Development, and R&D Strategy

EXELIXIS (EXEL)